ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (NASDAQ: RGEN) and ResMed (NYSE: RMD) are two stocks which could fit that bill with their proven track records and growing opportunities. Repligen offers a unique way to invest in the healthcare space. Operating in both the downstream and upstream processes of drug development, Repligen sells products in the areas of filtration, chromatography, process analytics, and proteins.
The heavy selling pressure might have exhausted for ResMed (RMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.